{"name":"UCB Biopharma SRL","slug":"ucb-biopharma-srl","ticker":"","exchange":"","domain":"ucbsrl.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Brivaracetam Film-coated tablet","genericName":"Brivaracetam Film-coated tablet","slug":"brivaracetam-film-coated-tablet","indication":"Adjunctive treatment of partial-onset seizures in patients with epilepsy","status":"phase_3"},{"name":"DZP","genericName":"DZP","slug":"dzp","indication":"Anxiety disorders","status":"phase_3"},{"name":"Staccato alprazolam","genericName":"Staccato alprazolam","slug":"staccato-alprazolam","indication":"Acute anxiety or panic episodes (Phase 3 development)","status":"phase_3"},{"name":"brivaracetam (BRV) tablet","genericName":"brivaracetam (BRV) tablet","slug":"brivaracetam-brv-tablet","indication":"Partial-onset seizures","status":"phase_3"},{"name":"zilucoplan (RA101495)","genericName":"zilucoplan (RA101495)","slug":"zilucoplan-ra101495","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ginisortamab","genericName":"ginisortamab","slug":"ginisortamab","indication":"Other","status":"phase_1"},{"name":"Brivaracetam oral solution","genericName":"Brivaracetam oral solution","slug":"brivaracetam-oral-solution","indication":"Other","status":"marketed"},{"name":"Lacosamide oral","genericName":"Lacosamide oral","slug":"lacosamide-oral","indication":"Other","status":"discontinued"},{"name":"Minzasolmin tablet formulation under fasting condition","genericName":"Minzasolmin tablet formulation under fasting condition","slug":"minzasolmin-tablet-formulation-under-fasting-condition","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ginisortamab","genericName":"ginisortamab","slug":"ginisortamab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brivaracetam Film-coated tablet","genericName":"Brivaracetam Film-coated tablet","slug":"brivaracetam-film-coated-tablet","phase":"phase_3","mechanism":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) in the brain to reduce neuronal excitability and prevent seizures.","indications":["Adjunctive treatment of partial-onset seizures in patients with epilepsy","Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy"],"catalyst":""},{"name":"Brivaracetam oral solution","genericName":"Brivaracetam oral solution","slug":"brivaracetam-oral-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DZP","genericName":"DZP","slug":"dzp","phase":"phase_3","mechanism":"DZP is a benzodiazepine that enhances GABAergic neurotransmission by potentiating the effect of GABA at GABA-A receptors in the central nervous system.","indications":["Anxiety disorders","Seizure disorders","Acute alcohol withdrawal","Muscle spasticity"],"catalyst":""},{"name":"Lacosamide oral","genericName":"Lacosamide oral","slug":"lacosamide-oral","phase":"discontinued","mechanism":"12.1 Mechanism of Action The precise mechanism by which lacosamide exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.","indications":[],"catalyst":""},{"name":"Minzasolmin tablet formulation under fasting condition","genericName":"Minzasolmin tablet formulation under fasting condition","slug":"minzasolmin-tablet-formulation-under-fasting-condition","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Staccato alprazolam","genericName":"Staccato alprazolam","slug":"staccato-alprazolam","phase":"phase_3","mechanism":"Staccato alprazolam is a rapidly-absorbed inhaled formulation of alprazolam that binds to GABA-A receptors in the central nervous system to enhance inhibitory neurotransmission.","indications":["Acute anxiety or panic episodes (Phase 3 development)"],"catalyst":""},{"name":"brivaracetam (BRV) tablet","genericName":"brivaracetam (BRV) tablet","slug":"brivaracetam-brv-tablet","phase":"phase_3","mechanism":"Brivaracetam is a selective, high-affinity SV2A receptor agonist.","indications":["Partial-onset seizures","Primary generalized tonic-clonic seizures"],"catalyst":""},{"name":"zilucoplan (RA101495)","genericName":"zilucoplan (RA101495)","slug":"zilucoplan-ra101495","phase":"phase_3","mechanism":"Zilucoplan is a sphingosine 1-phosphate receptor modulator.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQd1BSdGNva0tpWmhrQ0lfb0F3M3JGX093cTRZczBURnhXVmkwU1VFenJVcndjM1o5X1dVc3YtekpmczhDdHVTSUJ1V3BGdUpvNHdyZElfZjh3V291MEhiYWFqNHp6NDRJZE12ZmRIR1EtajFndjJEUjVXYjJQNENUcnlvZ3FQR21mRHI5Uk9hNFc4U0RZc0Z1bmNB?oc=5","date":"2026-04-07","type":"regulatory","source":"openPR.com","summary":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight - openPR.com","headline":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPNTlrMzJLMTUyX3RKRzJWYi1UX1RvSlZ2RUNEd2EtcDJmemhHLUlFZXQxSjcza29rTE9kUFRwRUN2ckdQS0tMcHhfUEN1VDUxeHZMQ1A4NWtqeUYwSFBpM1Y5ZUo3U1NqSk9nM2NtQXBwMDg0R2k3a2U4VTVkSktvR1pxVW8zdS1pQUZ5aExHU3dtY3Y3MTUyVmt2NzVITFBQUktxdHVORlM5WDFTcGZGYkJvM3pNc1ByYTFQT1ZNOUZBYkp6elFBbzNqT3RUQXBNU0FVYWoyemFGRUdUajJjTzlZX2kxX0phc1d2M0xoa1g5TWtvT1N0NVBWY2pZcERNd3N2ck5UV3FWU0MxUWtCbnd3?oc=5","date":"2026-02-16","type":"pipeline","source":"PR Newswire UK","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - PR Newswire UK","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxNVjNqUnRFNk51aWdrMUpSWHdaQUlaclNMb09JX1FSelUxb0R0b1JFX09OU29MMzh4cEFnTnljc2tINXBMWF9aWmpvUWI3T2lOeHRPLXZwRFBHdGxBdHE2Q3JjMzVmOS1raDJDbHNZeDJOU3pQS2RzMG9uOFBza2pnUTFaOFQ4c1FodE94ME5IUDZXZmlsR2hNaTZ0eTlwQ3RnTEZON0ZTV040OVRTM0Vtb3g3US1nTkZwQ0gtbGl1c0tmdE81U1pCS2tkZi03enNQSlpJUUtnRnRuVDBmUFpiUmI2V1Ffd1pFVFJNRWtfMWF2RDhNNUd5S0pQakcyM2hfclJmNG5ueW9FUjc2TGxCS2hfQThnMmdLM3BvWWlDVFlIX2dqVnJ6OC1IUllwOFBLejdTeGdEbjNXcktENV8xdGxlSUY?oc=5","date":"2026-01-29","type":"earnings","source":"Barchart.com","summary":"Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK, UCB Pharma - Barchar","headline":"Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Apti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQQzZONnNQY1N0YlhhTjlPVmNOS044ZzJZaDJhNXU1elZkTzh4ZXpKS09aN1hyOUxvei16Y2ZyTWNhTFRkQ0ZzVDBRTVhXSnNVcFllOXA5czhXdE0xZ0lYckYzRDZJczBod2JVM3FwRXlhREVseXN1d2NCOTZ0UmlCVGJCYjByV3RPLVBvdzVxU3p5WlZqVHIwODhTaHZuU1kwOENBX0NVbExvNWI3WF9WTGdBMlluQ21rdXRLZ2FWYTZrQU1TdExPRUh6a09TaUEyeDNIenRpOG41d2lUODBjdGNFMWpEN2JYWkh3NkZMT3M?oc=5","date":"2025-08-07","type":"pipeline","source":"The AI Journal","summary":"Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - The AI Journal","headline":"Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunoth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQMnZXNmsweU0zY1hhVk15eXRtZlAxWVhnQzA0SGVza1VHV3JVVzd3dHh6UWc0YU1tUjIxM0tLNDYxeHRvczdBR01zcmxpR25haGFaMTN6cS1kYzRHQ0Nyakw4X3NWVnBsZF9nNXFKN2NLM1g0MTdwWVFCMThLSVJOU21HV2hNWDRMS2g3RnJOblpTOTNHRU9DQkZtNnRoNEhiTElqaVFCZEhLVlFtS2ttdnM0dldaYmxuaUZyaGM3ektfSHdHal9aVkZhNmNSMzhORm9SMFVwMG1lMFhZRU1ZcWdpdlFObkdyYm84WDc0VjNJLWNtNE5qUGF3?oc=5","date":"2025-05-29","type":"regulatory","source":"PR Newswire","summary":"INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy| DelveInsight - PR Newswire","headline":"INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy| DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxORV9rNzJNLWJ2WWxXTktiM05GaUE3a3k2Z3dub2hlREZWUGdvVDBNT05Xbmh2U1lUWmFfMzFHaHhJY1Rhb2FmNWx6M3hwNW54YXQxeEZ3UFE1U1AyNy1JUVM4TTVLYVdEdGpkenJpaUZ1a2tyLUh6LWhMRGJjZVF5LUtVWmRPVTBVaXNKNXpTU2dNck5OaE1raVRYd1dwUXh4alRsemtURkZJc0VlUE1SdmpSYVpsZE16eXFuV3llaURzSVJ3MUtRYy1yYWFEaFJKZG42YndSbmhOV0U?oc=5","date":"2025-04-22","type":"pipeline","source":"PR Newswire","summary":"XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight - PR Newswire","headline":"XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxORHRTWkNwVGFoblVOUjNwRUxGWUc1M2xjdE5zc05TQ0dGTXJTdkpNQU5raXFBU3hkNmZseUFvMFdCUV8xWHh5Z242WFJVd1UzdU5LWTJIdDVYaHVkS3lrdU03MExId2p5Q19VSUdXVk5pajRkcnR4VlZNMmdyMnFPeVJHdXFMUzF5SXBUbjV2RGRwNlYtZDBqTDB1cENGNTgwbTlZY0gzazNqZ0p3alF1NFAyZlRwNldq?oc=5","date":"2025-03-25","type":"pipeline","source":"European Medical Journal","summary":"MOGAD Masterclass: Extending Approaches to Diagnosis and Management - European Medical Journal","headline":"MOGAD Masterclass: Extending Approaches to Diagnosis and Management","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQdzNUZFRCTVhoSUllbW1XakkxWEZseVhpUVpUMldwNkhMSGZSR0EtYlFZdTREMG5hVUpPWDRwMEJfNW94eU1JbzdXeUVubkl5MnZtUFZLWTMzME9kbW9yTnFkVWdtQjJLRjVBdWtxeHMyTDh6Rk5peXNDaHUxSWthampFTVdfbVowNExVUmFvMnpOYjlsVGs1MmpLbHlvbW56RmlBOE5zVnZzY2VVYnlrU2dST0k5RmVGTU9GdVI5eDBDd1lURE1vU2tBV1ZuR1lwUzNwanBWS29uNW5qZVVaVGtvT1VkdXVkU2swQlQxQVgtNWVkdk95UEVJUVRycDAzNk9mSjl0b1RZaXV1cGxzSlg1bUE3Q3FTWmVLVFgzWW9YQ2M5amNaeQ?oc=5","date":"2025-02-13","type":"trial","source":"GlobeNewswire","summary":"Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel - GlobeNewswire","headline":"Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNcEtNM0M5azBLZ2VIaVl5NUdvZ3BQbE40NFF3RDJjZVdRX28tTTBDY29DaGxudnltc0haYS1iVFJjaDZnLW1ua0RvWDJFeXk0NjNwVmpvQ1NNdHZzVDNSRmN3TmVweXFSc1hiNEV1VWtiSE1xX2RkcDRBRzltcUx4T05lalRza2RPTldBUGd4UW03Q2JMNUZGUWJnbUk0eWpDdGE4cGY4UjM1QWFvdUpMM1dydTBVZEtvUUNtdHFtR205NG5mYm9fYTRYSk1tX1NyY1BKZ0xFQW5UbzZZYmkzVkpFSTJjcWw0Z0RicTNfQQ?oc=5","date":"2025-01-23","type":"pipeline","source":"BioSpace","summary":"Ankylosing Spondylitis Market Size to Reach USD 10.03 Billion by 2035, Impelled by Advancements in Treatment Strategies - BioSpace","headline":"Ankylosing Spondylitis Market Size to Reach USD 10.03 Billion by 2035, Impelled by Advancements in Treatment Strategies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPcEZ3akphekFNenRhNHQ4LVJmWGVoaHRmRUlBYUVwb0VRSFBlQ2REa1JobGhaRGZYNmhKdDBueEdVUVQxTkhrSnRpNGtNbDdoVk1jTHJJSnFlVkZ6T2l3RGtsanpuVm5XWFNOQ250LWNDcGRPcmlZMWd5UW1WUHo5dzhJTnhBZnEtUHBaUEtJaXA2LWstc3ZZWUQ4LUtSRUxYQ01fN0xR?oc=5","date":"2024-12-10","type":"pipeline","source":"BioSpace","summary":"7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline - BioSpace","headline":"7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQTWZ0dk01XzUtMHdnQmE4UXY2RHFaMHV5VmNtWWl1VThnU2ZzTTh0M1VuOG5na0RUTUt3R3BieWZXZHRCLXJaVlBCTWtfcWp1UU9aM1VqVHJjWFBmbWc4ZWlIN1ROeDZGVjUyLVhGeHdDbjJGbHBVM0UtdTJCUmNaMzVUVEE5Mm5wMWFUMXJ2elZKVVF0bDIzM1F3RnE?oc=5","date":"2023-05-30","type":"regulatory","source":"Fierce Pharma","summary":"UPDATED: Belgium's UCB Pharma hit with FDA Form 483 after April inspection - Fierce Pharma","headline":"UPDATED: Belgium's UCB Pharma hit with FDA Form 483 after April inspection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNb0YxWjhyalNicnA3Uk1fZjdJVC1XNTF2SlZRbkd3UGxFTFBheEFKRHZIQThoZ21fcXE0Zmt3MWE2WmdmNV9HcVlELU1VcmVELU41VnppR2h2aGhBMkhBQ1NOVHphWWlkb1QxMkwyZTdHeVVrOFlYUGhaMWdzSGZkUGtUb1EycGEwcFRnWjEtMHdUUFRieFlZU2p5ZkluOHJyTl9zSlRHMA?oc=5","date":"2022-12-21","type":"regulatory","source":"lupin.com","summary":"Lupin Receives Approval from U.S. FDA for Brivaracetam Tablets - Lupin | Press Release - lupin.com","headline":"Lupin Receives Approval from U.S. FDA for Brivaracetam Tablets - Lupin | Press Release","sentiment":"positive"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_1":2,"phase_3":5,"marketed":1,"discontinued":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}